Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2020 07:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results Demonstrating Brilacidin’s COVID-19 Treatment Potential

Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing...
June 17, 2020 07:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line

Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...
June 11, 2020 07:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Collaborating with Regional Biocontainment Lab on Grant Application to Research Brilacidin as a Pan-Coronavirus Therapeutic

WAKEFIELD, Mass., June 11, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company and researchers...
May 26, 2020 08:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Receives Data from Public Health Research Institute Showing Brilacidin Inhibits SARS-CoV-2 (COVID-19) in a Human Cell Line

Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method...
April 27, 2020 09:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4

WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
March 17, 2020 07:30 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Brilacidin to be Researched as Possible Novel Coronavirus (COVID-19) Vaccine; Brilacidin Now Being Tested as Drug and Vaccine at Different Institutions

WAKEFIELD, Mass., March 17, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the...
March 12, 2020 08:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Announces Testing Procedures of Brilacidin Against Coronavirus (COVID-19)

WAKEFIELD, Mass., March 12, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today research procedures that one...
March 10, 2020 08:20 ET | Source: Innovation Pharmaceuticals Inc.

U.S. Regional Biocontainment Lab to Begin Testing of Brilacidin Against Coronavirus (COVID-19) Next Week

WAKEFIELD, Mass., March 10, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to inform shareholders that...
March 09, 2020 08:00 ET | Source: Innovation Pharmaceuticals Inc.

Innovation Pharmaceuticals Brilacidin Received by U.S. Regional Biocontainment Laboratory; Testing Against Coronavirus (COVID-19)

WAKEFIELD, Mass., March 09, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today the Company has been...